Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ticagrelor whole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Ticagrelor 90 mg as a whole tablet |
| B | EXPERIMENTAL | Ticagrelor 90 mg tablet crushed and suspended in water |
| C | EXPERIMENTAL | Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach |
| Name | Type | Description |
|---|---|---|
| Ticagrelor 90 mg whole tablet | DRUG | Ticagrelor 90 mg whole tablet administered as a single oral dose |
| Ticagrelor 90 mg tablet crushed | DRUG | Ticagrelor 90 mg crushed and suspended in water |
| Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube | DRUG | Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach |
Inclusion Criteria: * Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture * Have a body mass index between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg (110 pounds \[lbs\]) and no more than 100 kg (220 lbs). * Provi...
Ticagrelor whole refers to the intact 90 mg tablet form of ticagrelor, a small molecule drug developed by AstraZeneca PLC. It is also known as Ticagrelor 90 mg whole tablet. The whole tablet is studied to understand how the body absorbs the drug when the tablet is swallowed intact rather than crushed or chewed.
Ticagrelor whole targets P2RY12, the platelet P2Y12 receptor. It acts as a negative allosteric modulator at this receptor. By binding to P2RY12, ticagrelor inhibits platelet activation and aggregation, which is the basis for its antiplatelet activity.
Ticagrelor whole is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the company responsible for the development and clinical study of this tablet formulation.
Ticagrelor whole is in Phase 1 clinical development. It is an investigational formulation, and the Phase 1 program has been completed. The drug has not been approved for any indication based on the available development data.
Ticagrelor whole has been studied in one completed Phase 1 trial, NCT01887626, titled "Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration." The trial enrolled 36 healthy volunteers in the United Kingdom and was a randomized, controlled bioavailability study.